Loading stock data…
AIM
$0.44+0.03 (+7.93%)
Market OpenUpdated 2:59 PM EDT
AIM ImmunoTech Inc., an immuno-pharma company, engages in the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
AIM in the Healthcare sector is trading at $0.44 with a market capitalization of $11M. Wall Street consensus targets $5.25 (2 analysts), implying a +1101.6% move over the next 12 months. The stock is currently near its 52-week low of $0.21, remaining 66.9% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +1101.6% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $22,000↑ | $21,000↓ | $26,000↑ | $25,000↑ | $16,000 |
| Gross Profit | $18,000↑ | -$19,000↑ | -$42,000↓ | $15,000↑ | $6,000 |
| Operating Income | -$2.23M↑ | -$2.95M↓ | -$2.45M↑ | -$2.65M↑ | -$3.62M |
| Net Income | -$3.02M↑ | -$4.17M↓ | -$3.28M↓ | -$2.79M↑ | -$3.71M |
Peer Comparison
JNJUNHPFE
Fundamentals
AIM ImmunoTech Inc., an immuno-pharma company, engages in the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's flagship products are Ampli...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$10.66M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.24
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-624.75%
Volume
Today's trading volume
5.85M
Recent News
AIM Stock Soars Over 200% As Pancreatic Cancer Trial Hits Enrollment Milestone Early — CEO Sees 'Value-Inflection Period' Ahead
AIM ImmunoTech CEO Thomas K. Equels stated that the company is on track to complete the dosing of Ampligen.
Transcript: Aimia Q1 2026 Earnings Conference Call
On Wednesday, Aimia (TSX:AIM) discussed first-quarter financial results during its earnings call. The full transcript is provided below. This transcript is brought to you by Benzinga APIs. For real-time access to our entire catalog, please visit https://www.benzinga.com/apis/ for a consultation. Access the full call at https://app.webinar.net/EPYVWBVW2wk Summary AIM ImmunoTech Inc announced the divestiture of its specialty chemicals business, Bazzetto, and received regulatory approvals for the t
We Might See A Profit From Aimia Inc. (TSE:AIM) Soon
With the business potentially at an important milestone, we thought we'd take a closer look at Aimia Inc.'s ( TSE:AIM...
Aimia Q4 Earnings Call Highlights
Aimia (TSE:AIM) executives told investors the company’s transformation into what it described as a “useful permanent capital vehicle” advanced in the fourth quarter of 2025, with management highlighting solid operating results in its core businesses, a higher cash balance, and progress toward a plan
Thermo Fisher Scientific (TMO) Partners With AIM ImmunoTech on Phase 3 Cancer Trial
Thermo Fisher Scientific Inc. (NYSE:TMO) is one of the 10 Best Diagnostics and Research Stocks to Buy According to Analysts. On March 2, 2026, AIM ImmunoTech announced entering into an agreement with the PPD clinical research business of Thermo Fisher Scientific (TMO) to design a pivotal Phase 3 clinical trial for Ampligen. The study will […]